ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
The DJS Law Group announced a securities class action against ARS Pharmaceuticals (NASDAQ: SPRY), alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, with a class period of March 9 to June 24, 2026 and an October 5, 2026 lead plaintiff deadline. The complaint alleges ARS made false and misleading statements because it knew its timeline for CVS Caremark formulary and coverage approval decisions for neffy faced issues that would impact commercialization plans.
Key figures
- Class period end
- 2026-06-24
- Alleged violations
- Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5
- Class period start
- 2026-03-09
- Lead plaintiff deadline
- 2026-10-05
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.